Long-term follow-up of patients with poor prognosis germ cell tumor treated with early high-dose chemotherapy with hematopoietic progenitor cell support: A single-center experience

Bone Marrow Transplantation

Volumn 33, Issue 6, 2004, Pages 639-643

  De Giorgi, Ugo ^a   Rosti, G ^a   Papiani, G ^a   Marangolo, M ^a  

^a SANTA MARIA DELLE CROCI HOSPITAL   (Italy)

Author keywords

Hematopoietic progenitor cell support; High dose chemotherapy; Poor prognosis germ cell tumor

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; VINBLASTINE; VINCRISTINE;

ABDOMINAL PAIN; ADULT; ARTICLE; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER MORTALITY; CANCER REGRESSION; CANCER SURGERY; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG FATALITY; DRUG MEGADOSE; FEMALE; FEVER; FOLLOW UP; GERM CELL TUMOR; HEARING IMPAIRMENT; HEART FAILURE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION; ITALY; KIDNEY FAILURE; LEUKEMIA; LIVER TOXICITY; LONG TERM CARE; MALE; MYELODYSPLASIA; NEPHROTOXICITY; NEUTROPENIA; PARESTHESIA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; RESPIRATORY DISTRESS SYNDROME; STOMATITIS; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FOLLOW-UP STUDIES; GERMINOMA; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 1842587579     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704397     Document Type: Article

References (28)

1. Einhorn LH. Testicular cancer: An oncological success story. Clin Cancer Res 1997; 3: 2630-2632.
2. Sonneveld DJ, Hoekstra HJ, van Der Graaf WT et al. Improved long term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era. Cancer 2001; 91: 1304-1315.
3. Loehrer PJ, Gonin R, Nichols CR et al. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol 1998; 16: 2500-2504.
4. Bosl GJ, Geller NL, Cirrincione C et al. Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. Cancer Res 1983; 43: 3403-3407.
5. Birch R, Williams S, Cone A et al. Prognostic factors for favorable outcome in disseminated germ-cell tumors. J Clin Oncol 1986; 4: 400-407.
6. The Medical Research Council Working Party on Testicular Tumours. Prognostic factors in advanced non-seminomatous germ-cell testicular tumours. Results of a multicenter study. Lancet 1985; 1: 8-11.
7. International Germ Cell Cancer Collaborative Group. International germ cell consensus classification: A prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997; 15: 594-603.
8. Hartmann JT, Nichols CR, Droz JP et al. Prognostic variables for response and outcome in patients with extragonadal germ-cell tumors. Ann Oncol 2002; 13: 1017-1028.
9. Nichols CR, Williams SD, Loerher PJ et al. Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: A Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 1991; 9: 1163-1172.
10. de Wit R, Stoter G, Sleijfer DT et al. Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma: A randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. Br J Cancer 1995; 71: 1311-1314.
11. Kaye SB, Mead GM, Fosså SD et al. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor prognosis metastatic non-seminomatous germ cell tumor: A randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. J Clin Oncol 1998; 16: 692-701.
12. De Giorgi U, Rosti G, Papiani G et al. The status of high-dose chemotherapy with hematopoietic stem cell transplantation in patients with germ cell tumor. Haematologica 2002; 87: 95-104.
13. Dazzi C, Cariello A, Rosti G et al. Peripheral blood progenitor cell (PBPC) mobilization in heavily pretreated patients with germ cell tumors: A report of 34 cases. Bone Marrow Transplant 1999; 23: 529-532.
14. Miller AB, Hoogstraten B, Staquet M et al. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
15. Motzer RJ, Mazumdar M, Bajorin DF et al. High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Clin Oncol 1997; 15: 2546-2552.
16. Bokemeyer C, Harstrick A, Beyer J et al. The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ-cell tumours. German testicular Cancer Study Group. Semin Oncol 1998; 25: 24-32.
17. Kollmannsberger C, Nichols C, Bamberg M et al. First-line high-dose chemotherapy ± radiation therapy in patients with metastatic germ-cell cancer and brain metastases. Ann Oncol 2000; 11: 553-559.
18. Decatris MP, Wilkinson PM, Welch RS et al. High-dose chemotherapy and autologous haematopoietic support in poor risk non-seminomatous germ-cell tumours: An effective first-line therapy with minimal toxicity. Ann Oncol 2000; 11: 427-434.
19. Hartmann JT, Einhorn L, Nichols CR et al. Second-line chemotherapy in patients with relapsed extragonadal non-seminomatous germ cell tumors: Results of an international multicenter analysis. J Clin Oncol 2001; 19: 1641-1648.
20. Mandanas RA, Saez RA, Epstein RB et al. Long-term results of autologous; marrow transplantation for relapsed or refractory male or female germ cell tumors. Bone Marrow Transplant 1998; 21: 569-576.
21. Rosti G, De Giorgi U, Salvioni R et al. Salvage high-dose chemotherapy in patients with germ cell tumors: An Italian experience with 84 patients. Cancer 2002; 95: 131-137.
22. Motzer RJ, Mazumdar M, Sheinfeld J et al. Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. J Clin Oncol 2000; 18: 1173-1180.
23. Williams SD, Loehrer PJ, Nichols CR et al. Chemotherapy of male and female germ cell tumors. Semin Oncol 1992; 19: 19-23.
24. Kollmannsberger C, Beyer J, Droz JP et al. Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors. J Clin Oncol 1998; 16: 3386-3391.
25. Travis LB, Andersson M, Gospodarowicz M et al. Treatment-associated leukemia following testicular cancer. J Natl Cancer Inst 2000; 14: 1165-1171.
26. Strumberg D, Brugge S, Korn MW et al. Evaluation of longterm toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. Ann Oncol 2002; 13: 229-236.
27. Chevreau C, Droz JP, Pico JL et al. Early intensified chemotherapy with autologous bone marrow transplantation in first line treatment of poor risk non-seminomatous germ cell tumours. Preliminary results of a French randomized trial. Eur Urol 1993; 23: 213-218.
28. Bokemeyer C, Kollmannsberger C, Meisner C et al. First-line high-dose chemotherapy compared with standard-dose PEB/ VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis. J Clin Oncol 1999; 17: 3450-3456.